BIAF down 32.2% on Sep 9 2026 (dilution risk)
BIAF-32.2%on Wed Sep 9 2026
bioAffinity Technologies, Inc. Common Stock was down 32.2% on the day at $10.36, ranked #3 on 6.1× its usual five-minute volume, when TapeRank recorded this drop at 08:02 ET during the pre-market session.
THE DAY ON THE LIST · 1 EVENT
- 08:02 ETMOVER · PRE-MARKET
$10.36 · ▼ 32.2% ON THE DAY · 6.1× 5M RVOL · RANK #3
DILUTION RISKCONFIDENCE4/5BIAF is down nearly 40% premarket following a 424B3 prospectus supplement that registers resale shares tied to an August 2026 private placement, effectively confirming a large overhang of freely tradable stock. The filing itself contains no new operational or business catalyst, only disclosure of financing mechanics and selling stockholders.
WHYA resale registration from a prior private placement does not typically justify a 39% single-day decline, pointing to dilution-driven selling pressure far outsized relative to the administrative nature of the filing.ANALYZED 07:39 ET · 22 MIN AGO · ANTHROPIC/CLAUDE-SONNET-5THE ROW AND SESSION LEVELS AT 08:02 ET
LAST10.36DAY▼ 32.2%5 MIN▲ 9.54%5M RVOL6.1×5M $VOL$546KFLOAT*592KRANK#3SESSIONPRE-MARKETVWAP9.42HOD10.63LOD8.36OR HIGH—OR LOW—PREV CLOSE15.27PM HIGH10.21PM LOW8.59GAP▼ 30.39%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
THE SESSION
- 09:30 ETOpened at $10.90, -28.6% on the previous close of $15.27
- 09:41 ETRegular-session high, $12.32
- 11:16 ETRegular-session low, $10.09
- 15:59 ETLast trade of the regular session, $10.59, -30.6% on the previous close of $15.27
- Volume: 7.0M shares in regular hours, 3.2M before the open
BIAF opened at $10.90, already down sharply from the prior close of $15.27, then spiked to $12.32 at 09:41 ET before sellers took over. Shares slid through the morning to a low of $10.09 at 11:16 ET and drifted into the close at $10.59, finishing down about 30.6% on the day with no halts recorded. TapeRank's read tied the move to a 424B3 prospectus supplement filed the prior afternoon registering resale shares from an August private placement, flagging dilution risk from the newly freely tradable stock rather than any operational catalyst, with 4/5 confidence.
WRITTEN THU OCT 15 2026 17:43 ET BY ANTHROPIC/CLAUDE-SONNET-5 FROM THE FACTS ON THIS PAGE
FILINGS · 24H BEFORE THE MOVE
- TUE 16:30 ET424B3 — Prospectus supplementSEC 424B3
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list